Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam Sells 7,476 Shares of Stock
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam Sells 7,476 Shares of Stock
Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Rating) CFO Kamran Alam sold 7,476 shares of the stock in a transaction dated Thursday, August 18th. The stock was sold at an average price of $3.87, for a total value of $28,932.12. Following the transaction, the chief financial officer now owns 290,645 shares of the company's stock, valued at approximately $1,124,796.15. The transaction was disclosed in a filing with the SEC, which is available at this link.
泰莎基因療法公司(納斯達克代碼:TSHA-GET評級)首席財務官卡姆蘭·阿拉姆在日期為8月18日(星期四)的交易中出售了7,476股該股。這隻股票的平均售價為3.87美元,總價值為28,932.12美元。交易完成後,這位首席財務官現在擁有290,645股公司股票,價值約1,124,796.15美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過以下鏈接獲得。
Kamran Alam also recently made the following trade(s):
卡姆蘭·阿拉姆最近還進行了以下交易:
- On Monday, August 22nd, Kamran Alam sold 9,717 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $3.50, for a total value of $34,009.50.
- 8月22日,星期一,卡姆蘭·阿拉姆出售了9,717股泰莎基因療法股票。這隻股票的平均售價為3.50美元,總價值為34,009.50美元。
Taysha Gene Therapies Trading Down 8.3 %
泰莎基因療法降價8.3%
Shares of NASDAQ:TSHA opened at $3.43 on Tuesday. Taysha Gene Therapies, Inc. has a 52-week low of $2.33 and a 52-week high of $21.90. The company has a market capitalization of $140.95 million, a P/E ratio of -0.71 and a beta of 0.99. The company has a 50-day simple moving average of $4.01 and a 200 day simple moving average of $4.73. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.79 and a current ratio of 1.79.
納斯達克:臺積電週二開盤報3.43美元。塔莎基因療法公司的股價為2.33美元,為52周低點,52周高點為21.90美元。該公司市值為1.4095億美元,市盈率為-0.71,貝塔係數為0.99。該公司的50日簡單移動均線切入位在4.01美元,200日簡單移動均線切入位在4.73美元。該公司的負債權益比率為1.15,速動比率為1.79,流動比率為1.79。
Analysts Set New Price Targets
分析師設定新的價格目標
Institutional Investors Weigh In On Taysha Gene Therapies
機構投資者對泰莎基因療法的看法
Several hedge funds have recently bought and sold shares of TSHA. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at about $259,000. Northern Trust Corp lifted its position in Taysha Gene Therapies by 1.4% during the fourth quarter. Northern Trust Corp now owns 214,970 shares of the company's stock worth $2,504,000 after acquiring an additional 3,042 shares during the last quarter. ProShare Advisors LLC acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $121,000. GSA Capital Partners LLP acquired a new stake in Taysha Gene Therapies during the fourth quarter worth approximately $476,000. Finally, Virtus ETF Advisers LLC lifted its position in Taysha Gene Therapies by 39.3% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,519 shares of the company's stock worth $134,000 after acquiring an additional 3,251 shares during the last quarter. 46.05% of the stock is currently owned by institutional investors and hedge funds.
幾家對衝基金最近買賣了TSHA的股票。三菱UFJ國賽資產管理有限公司在第四季度收購了泰莎基因療法公司的新股份,價值約25.9萬美元。北方信託公司在第四季度將其在塔莎基因療法的頭寸提高了1.4%。Northern Trust Corp目前持有214,970股該公司股票,價值2,504,000美元,此前該公司在上個季度又收購了3,042股。ProShare Advisors LLC在第四季度收購了塔莎基因療法公司的新股份,價值約121,000美元。GSA Capital Partners LLP在第四季度收購了塔莎基因療法公司的新股份,價值約476,000美元。最後,Virtus ETF Advisers LLC在第四季度將其在塔莎基因療法的地位提高了39.3%。Virtus ETF Advisers LLC現在擁有11,519股該公司的股票,價值13.4萬美元,在上個季度額外購買了3,251股。46.05%的股票目前由機構投資者和對衝基金持有。
Taysha Gene Therapies Company Profile
泰莎基因療法公司簡介
(Get Rating)
(獲取評級)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.
泰莎基因療法公司是一家基因治療公司,專注於開發基於腺相關病毒的基因療法並將其商業化,用於治療中樞神經系統單基因疾病。它主要開發用於治療巨大軸索性神經病的TSHA-120;用於治療Rett綜合徵的TSHA-102;用於治療CLN1疾病的TSHA-121;用於治療CLN1疾病的TSHA-118;用於治療SLC13A5缺乏症的TSHA-105;以及用於治療GM2神經節苷脂缺乏的TSHA-101。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Taysha Gene Therapies (TSHA)
- MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
- Should You Buy These Copper Stocks Ahead Of Monster Demand?
- Three Industrial Stocks That Can Weather a Stormy Recession
- Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
- Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names
- 免費獲取StockNews.com關於塔莎基因療法的研究報告(TSHA)
- MarketBeat播客:股票投資組合中的夢幻足球策略
- 你應該在怪物需求之前買入這些銅庫存嗎?
- 三隻能夠渡過風暴般的衰退的工業股票
- 牀上洗澡和肉食之外:Bynd是下一個大空頭嗎?
- Denbury因出售傳言而上漲,但落後於其他能源公司
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
接受《泰莎基因療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對塔莎基因療法和相關公司評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。